Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetrizoic acid is a historical iodinated contrast medium belonging to the class of ionic, high-osmolar contrast agents (HOCA). Developed in the 1950s, it was one of the first triiodinated benzoic acid derivatives used for diagnostic imaging, specifically in procedures such as intravenous urography, retrograde pyelography, and hysterosalpingography. It functions by absorbing X-rays due to its high iodine content, thereby enhancing the visualization of internal structures. However, its high osmolality was associated with significant adverse effects, including vascular pain and organ toxicity, leading to its replacement by more modern, non-ionic, and low-osmolar contrast media.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetrizoic acid.